Dr.Saro Sarkisian's second opinion

Saro Sarkisian

United States, 17 years of experience

Oncology

Area of expertise

Specialty

Oncology

Subspecialty

Medical Oncology, Hematologic Oncology

Diseases

Lung Cancer, Genitourinary Cancers, Lymphoma, Myeloma, Leukemia, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Liver Cancer, Esophageal Cancer, Colorectal Cancer, Small Bowel Cancer, Gallbladder Cancer

Procedures Performed

Bone Marrow Aspiration

Bone Marrow Biopsy

Experience

Hematologist/Medical Oncologist, Frederick Health

Frederick, MD, USA. From 2021

Hematology/Medical Oncology Fellow, Lehigh Valley Cancer Institute

Allentown, PA, USA. 2018 - 2021

Clinical Assistant Professor of Medicine, Hematology/Oncology Hospitalist, University of Pittsburgh Cancer Institute

Pittsburgh, PA, USA. 2017 - 2018

Assistant Medical Director, Palliative Care Program, Excela Health

Greensburg, PA, USA. 2015 - 2017

Member, Excela Health Medical Group Advisory Board

Greensburg, PA, USA. 2015 - 2017

Education

Masters of Health Administration, Capella University

2017

MD, University of Aleppo, School of Medicine

2009

Biography

Dr. Sarkisian is an experienced medical oncologist and hematologist with more than 10 years of practice. He received his MD from the University of Aleppo, School of Medicine, and completed his Hematology and Medical Oncology Fellowship at the Lehigh Valley Cancer Institute. He also holds a Master of Health Administration from Capella University. Throughout his career, Dr. Sarkisian has held various positions, such as Clinical Assistant Professor of Medicine, Hematology/Oncology Hospitalist at

Affiliations

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

Publications

Rare Presentation of a Rare Disease: Signet Ring Cell Adenocarcinoma in Rothmund-Thomson Syndrome

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma treated with Erdafitinib

Palbociclib-induced pneumonitis: A Case Report and Review of the Literature

Current Clinical Trials in the Treatment of Advanced Melanomas

MEK inhibitors for the Treatment of NRAS Mutant Melanoma

You’re only one click away from a life-changing journey

Virtual health assistant powered by AI
350+ world-renowned Doctors

© 2024 Docus. All rights reserved.